872 related articles for article (PubMed ID: 27522556)
1. Overall survival is increased among stage III pancreatic adenocarcinoma patients receiving neoadjuvant chemotherapy compared to surgery first and adjuvant chemotherapy: An intention to treat analysis of the National Cancer Database.
Shubert CR; Bergquist JR; Groeschl RT; Habermann EB; Wilson PM; Truty MJ; Smoot RL; Kendrick ML; Nagorney DM; Farnell MB
Surgery; 2016 Oct; 160(4):1080-1096. PubMed ID: 27522556
[TBL] [Abstract][Full Text] [Related]
2. Value of lymph node positivity in treatment planning for early stage pancreatic cancer.
Tran Cao HS; Zhang Q; Sada YH; Silberfein EJ; Hsu C; Van Buren G; Chai C; Katz MHG; Fisher WE; Massarweh NN
Surgery; 2017 Sep; 162(3):557-567. PubMed ID: 28666686
[TBL] [Abstract][Full Text] [Related]
3. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant therapy versus upfront surgery for resected pancreatic adenocarcinoma: A nationwide propensity score matched analysis.
de Geus SW; Eskander MF; Bliss LA; Kasumova GG; Ng SC; Callery MP; Tseng JF
Surgery; 2017 Mar; 161(3):592-601. PubMed ID: 28341441
[TBL] [Abstract][Full Text] [Related]
5. Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy.
Christians KK; Heimler JW; George B; Ritch PS; Erickson BA; Johnston F; Tolat PP; Foley WD; Evans DB; Tsai S
Surgery; 2016 Mar; 159(3):893-900. PubMed ID: 26602840
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis.
Mokdad AA; Minter RM; Zhu H; Augustine MM; Porembka MR; Wang SC; Yopp AC; Mansour JC; Choti MA; Polanco PM
J Clin Oncol; 2017 Feb; 35(5):515-522. PubMed ID: 27621388
[TBL] [Abstract][Full Text] [Related]
7. Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy.
Addeo P; Rosso E; Fuchshuber P; Oussoultzoglou E; De Blasi V; Simone G; Belletier C; Dufour P; Bachellier P
Oncology; 2015; 89(1):37-46. PubMed ID: 25766660
[TBL] [Abstract][Full Text] [Related]
8. Multi-agent neoadjuvant chemotherapy improves survival in early-stage pancreatic cancer: A National Cancer Database analysis.
Deng A; Wang C; Cohen SJ; Winter JM; Posey J; Yeo C; Basu Mallick A
Eur J Cancer; 2021 Apr; 147():17-28. PubMed ID: 33607382
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant
Hashmi A; Kozick Z; Fluck M; Hunsinger MA; Wild J; Arora TK; Shabahang MM; Blansfield JA
Am Surg; 2018 Sep; 84(9):1439-1445. PubMed ID: 30268172
[TBL] [Abstract][Full Text] [Related]
10. Can Neoadjuvant Therapy in Pancreatic Cancer Increase the Pool of Patients Eligible for Pancreaticoduodenectomy?
Hackert T; Ulrich A; Büchler MW
Adv Surg; 2017 Sep; 51(1):1-10. PubMed ID: 28797331
[No Abstract] [Full Text] [Related]
11. Five-Year Actual Overall Survival in Resected Pancreatic Cancer: A Contemporary Single-Institution Experience from a Multidisciplinary Perspective.
Picozzi VJ; Oh SY; Edwards A; Mandelson MT; Dorer R; Rocha FG; Alseidi A; Biehl T; Traverso LW; Helton WS; Kozarek RA
Ann Surg Oncol; 2017 Jun; 24(6):1722-1730. PubMed ID: 28054192
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: A propensity score matched analysis.
Yadav S; Xie H; Bin-Riaz I; Sharma P; Durani U; Goyal G; Borah B; Borad MJ; Smoot RL; Roberts LR; Go RS; McWilliams RR; Mahipal A
Eur J Surg Oncol; 2019 Aug; 45(8):1432-1438. PubMed ID: 30914290
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcomes and prognostic factors in neuroendocrine carcinomas of the pancreas: Morphology matters.
Crippa S; Partelli S; Bassi C; Berardi R; Capelli P; Scarpa A; Zamboni G; Falconi M
Surgery; 2016 Mar; 159(3):862-71. PubMed ID: 26602841
[TBL] [Abstract][Full Text] [Related]
14. Carbohydrate Antigen 19-9 Elevation in Anatomically Resectable, Early Stage Pancreatic Cancer Is Independently Associated with Decreased Overall Survival and an Indication for Neoadjuvant Therapy: A National Cancer Database Study.
Bergquist JR; Puig CA; Shubert CR; Groeschl RT; Habermann EB; Kendrick ML; Nagorney DM; Smoot RL; Farnell MB; Truty MJ
J Am Coll Surg; 2016 Jul; 223(1):52-65. PubMed ID: 27049786
[TBL] [Abstract][Full Text] [Related]
15. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study.
Labori KJ; Katz MH; Tzeng CW; Bjørnbeth BA; Cvancarova M; Edwin B; Kure EH; Eide TJ; Dueland S; Buanes T; Gladhaug IP
Acta Oncol; 2016; 55(3):265-77. PubMed ID: 26213211
[TBL] [Abstract][Full Text] [Related]
16. External radiation is associated with limited improvement in overall survival in resected margin-negative stage IIB pancreatic adenocarcinoma.
Kantor O; Talamonti MS; Lutfi W; Wang CH; Winchester DJ; Marsh R; Prinz RA; Baker MS
Surgery; 2016 Dec; 160(6):1466-1476. PubMed ID: 27614417
[TBL] [Abstract][Full Text] [Related]
17. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis.
Sugimoto M; Takahashi N; Farnell MB; Smyrk TC; Truty MJ; Nagorney DM; Smoot RL; Chari ST; Carter RE; Kendrick ML
J Surg Oncol; 2019 Nov; 120(6):976-984. PubMed ID: 31452208
[TBL] [Abstract][Full Text] [Related]
18. Perioperative chemotherapy is associated with a survival advantage in early stage adenocarcinoma of the pancreatic head.
Lutfi W; Talamonti MS; Kantor O; Wang CH; Liederbach E; Stocker SJ; Bentrem DJ; Roggin KK; Winchester DJ; Marsh R; Prinz RA; Baker MS
Surgery; 2016 Sep; 160(3):714-24. PubMed ID: 27422328
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant therapy for resectable pancreatic cancer.
Raut CP; Evans DB; Crane CH; Pisters PW; Wolff RA
Surg Oncol Clin N Am; 2004 Oct; 13(4):639-61, ix. PubMed ID: 15350939
[TBL] [Abstract][Full Text] [Related]
20. Pancreatic adenocarcinoma: effects of neoadjuvant therapy on post-pancreatectomy outcomes - an American College of Surgeons National Surgical Quality Improvement Program targeted variable review.
Czosnyka NM; Borgert AJ; Smith TJ
HPB (Oxford); 2017 Oct; 19(10):927-932. PubMed ID: 28747265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]